Support for this assumption comes from preclinical research showing that the oral administration of TGF-β1 can protect against gastrointestinal diseases and lower systemic IL6 and IFN-γ levels based on a necrotizing enterocolitis model [39] and summarized in a review on maternal TGF-β and immunological outcomes [40]. The gene discussed is IL6; the disease is necrotizing enterocolitis.